The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
- Conditions
- Prostate Cancer
- Registration Number
- NCT06064149
- Lead Sponsor
- Vivek Narayan
- Brief Summary
- The overarching goal of this trial is to develop mechanisms to improve cardiovascular care among such prostate cancer patients receiving ADT by increasing patient awareness of individualized cardiovascular risk estimates and mitigation opportunities. Patients will be given access to a web-based quality improvement tool to educate patients of cardiovascular risks in prostate cancer and to inform them of their individualized, estimated cardiovascular risk and guideline-based risk mitigation recommendations. 
 The study will assess the feasibility of this web-based application as a cardiovascular education tool for patients with prostate cancer.
 The study will also evaluate if completion of the web-based tool improves cardiovascular care access and risk mitigation for patients with prostate cancer.
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 100
- Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of ADT
- Patients must be able to read and understand English.
n/a
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
- Name - Time - Method - CARE-PC Web-Based Application Completion Rate - 18 months - Completion rate measured as the proportion of participants successfully completing the web-based application out of the total number of subjects approached. 
- Secondary Outcome Measures
- Name - Time - Method - Percent accuracy of patient-derived CV- and prostate cancer-related data elements - 18 months - Accuracy assessed through parallel medical chart review by cardiology and oncology clinicians - Proportion of participants having changes in CV risk-reducing medications within 6 months of CARE-PC application participation. - 18 months - Proportion of participants having changes in CV risk-reducing medications assessed through parallel medical chart review by cardiology and oncology clinicians within 6 months post-application survey completion - Prevalence of CV risk factors/disease at the time of CARE-PC web-based application participation - 18 months - Prevalence assessed through parallel medical chart review by cardiology and oncology clinicians - Proportion of participants engaging in CV care within 6 months of CARE-PC web application participation - 18 months - CV care engagement assessed through medical chart review by investigators within 6 months post-application survey completion - Patient acceptance and perception of the web-based application - 18 months - Acceptance/perception measured by brief embedded survey following participation in the web-based application - Proportion of participants with current cardiologist involvement in CV care at the time of web-based application participation - 18 months - Patient reported cardiologist involvement via CARE-PC application at time of application survey completion 
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
- Abramson Cancer Center of the University of Pennsylvania 🇺🇸- Philadelphia, Pennsylvania, United States Abramson Cancer Center of the University of Pennsylvania🇺🇸Philadelphia, Pennsylvania, United StatesVivek Narayan, MDContact215-360-0737PennCancerTrials@emergingmed.com
